For decades, checking LDL cholesterol and other common atherosclerotic factors has been the primary way to assess cardio- vascular disease risks.

Now there may be an even better way.

Recent studies^1-3 and updated guidelines⁴ have increasingly focused on a more precise approach to cardiovascular risk assessment:

Apolipoprotein B… also known as ApoB.

In parallel with other blood markers, ApoB testing has gained attention as a complementary way to determine cardio- vascular risk and evaluate the effectiveness of treatments.^1,5,6

The Problem: Atherosclerosis

Cardiovascular disease is frequently driven by atherosclerosis, the buildup of plaque within artery walls that can restrict or block blood flow.⁷

When plaque builds up in the arteries supplying the heart, it causes coronary artery disease and can trigger chest pain or heart attacks. In the arms and legs, it leads to peripheral vascular disease, a painful and debilitating condition.⁷

In brain arteries, it causes cerebrovascular disease and increases the risk of ischemic stroke and transient ischemic attacks (TIAs).⁷

Atherosclerotic plaque is largely made up of accumulations of lipoproteins that often contain cholesterol and triglycerides, but also contains immune cells that contribute to inflammation as well as dead and dying cells of various types.^8,9

Although we tend to say that blood tests check our “lipids,” they are in fact testing lipoproteins like low-density lipoprotein (LDL) and high-density lipoprotein (HDL). More informed doctors are including a test for another lipoprotein, ApoB.

Testing ApoB allows doctors to estimate the risk of developing atherosclerosis and cardiovascular disease.

LDL Cholesterol Explained

Atherosclerosis often begins when lipoproteins deliver lipids to the arterial walls.¹⁰

But some lipoproteins are particularly pro-athero- genic. This means they are more likely to enter and remain within artery walls, contributing to athero-sclerosis.^8,10

One of the most well-studied pro-atherogenic lipoproteins is LDL (low-density lipoprotein).

Higher levels of LDL cholesterol, often called “bad” cholesterol, are a well-established risk for cardiovascular disease.^1,11 (HDL, or high-density lipoprotein, can carry excess cholesterol away from the blood and artery walls to be excreted, so that it is sometimes called “good cholesterol.”)¹²

Measuring LDL cholesterol levels via a blood test, generally in combination with assessment of other risk factors, allows physicians to estimate patients’ risk of developing cardiovascular disease or suffering cardiovascular events like heart attack, stroke, or cardiovascular-related death.¹

The effectiveness of cholesterol-lowering drugs like statins can be monitored by re-measuring LDL cholesterol to ensure levels are coming down.

But several other lipoproteins are also pro-atherogenic, so that measuring only LDL cholesterol gives an incomplete picture of cardiovascular risk.¹

In recent years, scientists have turned more and more attention to a more precise and accurate way to assess cardiovascular risk: apolipoprotein B (ApoB).^1,11

Why ApoB Is More Accurate

ApoB is a protein found in the outer shell of atherogenic (cardiovascular-disease promoting) lipoproteins. Each of the following pro-atherogenic lipoproteins contains one molecule of ApoB:¹¹

• LDL,
• VLDL (very-low-density lipoprotein),
• IDL (intermediate-density lipoprotein),
• Chylomicrons, and
• Lipoprotein (a), or Lp(a).

HDL does not contain ApoB.

While testing LDL levels tells you the amount of cholesterol in the low-density variety of lipoproteins, measuring ApoB provides an estimate of the total number of all pro-atherogenic lipoprotein particles in the blood.^1,8,10

As a result, ApoB may better represent the overall risk for cardiovascular disease and events.^4,8,13

For example, people with metabolic disease, including metabolic syndrome, insulin resistance, and type 2 diabetes, often have a disproportionately high number of atherogenic lipoprotein particles despite normal or near‑normal LDL cholesterol levels.¹ An ApoB test would detect these pro-atherogenic particles and elevated levels would indicateincreased risk of atherosclerosis.

In an analysis of results from the United States National Health and Nutrition Examination Survey of 2011– 2018, close to 42% of U.S. adults aged 20 years and older had metabolic syndrome.¹⁴ Thus, it is possible that for many metabolic syndrome adults, ApoB levels could offer a better estimate of cardiovascular risk than LDL cholesterol.

What Studies Show

A human clinical study published in 2000 was one of the first to suggest that elevated ApoB is a better predictor of major cardiovascular events, compared to high LDL cholesterol, in people taking statins for cholesterol.¹⁵

Many studies published since then support the value and accuracy of ApoB testing.^1,11

One review published in 2025 analyzed data from 15 studies including nearly 600,000 participants. In nine of those studies, LDL cholesterol was compared to ApoB as a predictor of cardiovascular risk. In all nine of those studies, ApoB was the superior biomarker.¹¹

The authors concluded that ApoB may be considered as the primary measure in estimating cardiovascular risk as well as in assessing the adequacy of treatments to lower lipid levels.¹¹

Another large observational study of over 40,000 participants published in 2025 compared ApoB testing with LDL-P, which measures the number of LDL particles in the blood. (Typical LDL cholesterol tests measure the amount of cholesterol carried by LDL particles, not the number of particles.)¹

This analysis found that when LDL-P and ApoB disagree, ApoB is the more accurate predictor of risk for major cardiovascular events and coronary artery events.¹

With findings like these accumulating, many experts encourage physicians to consider ApoB as an additional estimate of cardiovascular disease risk. The National Lipid Association now recognizes ApoB as a stronger predictor of cardiovascular risk when conventional lipoprotein measures give results that conflict with the ApoB levels.⁶

Elevated LDL cholesterol remains a major risk factor for cardiovascular disease. Adding an annual ApoB test can provide a more comprehensive assessment for cardiovascular disease risk and assess whether lipid-lowering interventions are working.

Summary

LDL cholesterol levels have long been used to estimate risk of cardiovascular disease. But research suggests that adding another test is likely a more accurate and precise approach.

Apolipoprotein B (ApoB) is found within the surface of LDL and other atherogenic lipoproteins. Testing for ApoB offers an estimate of the total number of lipid particles in blood that contribute to atherosclerosis development and progression.

Studies confirm that ApoB is an excellent and reliable indicator of risk for cardiovascular disease and cardiovascular events like stroke and heart attack.

Many experts now recommend testing ApoB and cholesterol levels to estimate cardiovascular risk and monitor the effectiveness of lipid-lowering medications.

ApoB was long ago added to the comprehensive Male and Female Blood Test panels used by many readers of this magazine.

If you have any questions on the scientific content of this article, please call a Life Extension Wellness Specialist at 1-866-864-3027.

References

1. Epstein E, Ekpo E, Evans D, et al. Apolipoprotein B outperforms low density lipoprotein particle number as a marker of cardiovascular risk in the UK Biobank. Eur J Prev Cardiol. 2025 Sep 1.
2. Luebbe S, Sniderman AD, Moran AE, et al. Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy. JAMA. 2026 Apr 8.
3. Sniderman AD, Pencina MJ, Thanassoulis G. ApoB and Lp(a): core measures to assess cardiovascular risk. Eur Heart J. 2025 Jul 14;46(27):2702-4.
4. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Jacc. 2026;0(0).
5. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88.
6. Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024 Sep-Oct;18(5):e647-e63.
7. Jebari-Benslaiman S, Galicia-Garcia U, Larrea-Sebal A, et al. Pathophysiology of Atherosclerosis. Int J Mol Sci. 2022 Mar 20;23(6).
8. Araujo G, Valencia LM, Martin-Ozimek A, et al. Atherosclerosis: from lipid-lowering and anti-inflammatory therapies to targeting arterial retention of ApoB-containing lipoproteins. Front Immunol. 2025;16:1485801.
9. Boren J, Packard CJ, Binder CJ. Apolipoprotein B-containing lipoproteins in atherogenesis. Nat Rev Cardiol. 2025 Jun;22(6):399-413.
10. Hurt-Camejo E, Camejo G. ApoB-100 Lipoprotein Complex Formation with Intima Proteoglycans as a Cause of Atherosclerosis and Its Possible Ex Vivo Evaluation as a Disease Biomarker. J Cardiovasc Dev Dis. 2018 Jul 1;5(3).
11. Sehayek D, Cole J, Bjornson E, et al. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. J Clin Lipidol. 2025 Jul-Aug;19(4):844-59.
12. von Eckardstein A, Nordestgaard BG, Remaley AT, et al. High-density lipoprotein revisited: biological functions and clinical relevance. Eur Heart J. 2023 Apr 21;44(16):1394-407.
13. Johannesen Camilla Ditlev L, Mortensen Martin B, Langsted A, et al. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. JACC. 2021 2021/03/23;77(11):1439-50.
14. Liang X, Or B, Tsoi MF, et al. Prevalence of metabolic syndrome in the United States National Health and Nutrition Examination Survey 2011-18. Postgrad Med J. 2023 Aug 22;99(1175):985-92.
15. Gotto AM, Jr., Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000 Feb 8;101(5):477-84.